Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Deep-Learning and HPC to Boost Biomedical Applications for Health

DeepHealth

Health scientific discovery and innovation are expected to quickly move forward under the so called “fourth paradigm of science”, which relies on unifying the traditionally separated and heterogeneous high-performance computing and big data analytics environments. Under this paradigm, the DeepHealth project will provide HPC computing power at the...

Funding Programme
Start Date
End Date
Total Funding
€ 14 642 324
European Countries Involved

Dementia: Intersectorial Strategy for Training and Innovation Network for Current Technology (DISTINCT)

DISTINCT

The main aim of DISTINCT will develop a premier quality multi-disciplinary, multi-professional and intersectorial education and training research framework for Europe aimed at improving technology and care for people with dementia and their carers, and to use coherent themes an.d interrelated ESRs within DISTINCT to provide the evidence to show how...

Funding Programme
Start Date
End Date
Total Funding
€ 3 998 048
European Countries Involved

Designing for People with Dementia: designing for mindful self-empowerment and social engagement

MinD

This project aims to help people with dementia engage in social contexts to improve psychosocial wellbeing. People who are affected by Alzheimer’s disease or other dementias often face cognitive, behavioural and psychosocial difficulties, including impairment and degeneration of memory and of perceptions of identity. In a social context, this can...

Funding Programme
Start Date
End Date
Total Funding
€ 549 000
European Countries Involved

Developing new therapies for Batten disease

BATCure

The goal of BATCure is to advance the development of new therapeutic options for a group of rare lysosomal diseases - neuronal ceroid lipofuscinoses (NCL) or Batten disease. There are > thousand affected across Europe, with a combined incidence of c.1:100 000. The NCLs are devastating and debilitating genetic disorders that mainly affect children...

Funding Programme
Start Date
End Date
Total Funding
€ 6 000 681
European Countries Involved

Development of a multiplex nanofluidic assay for selective detection and monitoring of Alzheimer's disease biomarkers

NANOASSAY

In this work, I propose the use of a nano/microfluidic system to detect biomarkers relevant to Alzheimer’s disease (AD). The use of this system could give earlier and more accurate diagnoses, as well as provide the opportunity for therapeutic interventions and effective disease monitoring. Prior to the diagnosis of dementia and even before the...

Funding Programme
Start Date
End Date
Total Funding
€ 168 794
European Countries Involved

Development of a novel FGL therapy and translational tests for regenerative treatment of neurological disorders

NEUROFGL

Neurodegenerative disorders such as, Alzheimer’s disease (AD), Mild Cognitive Impairment (MCI), stroke, Traumatic Brain Injury (TBI) and chronic stress create a major economic burden to society and a substantial reduction in quality of life for patients and families. The development of neuroregenerative therapies is notoriously difficult and...

Funding Programme
Start Date
End Date
Total Funding
€ 7 807 910
European Countries Involved

Development of a Novel Multicellular In Vitro Model of Alzheimer’s disease-like Blood-Brain Barrier

NAB3

A striking challenge in diagnosis and therapy of neurodegenerative diseases is the design of drugs capable of crossing the blood-brain barrier (BBB), a tightly regulated barrier that prevents the passage of drugs from the blood to the brain. In vitro cellular BBB models are available, but they mimic only healthy conditions without taking into...

Funding Programme
Start Date
End Date
Total Funding
€ 812 488
European Countries Involved

Devising a personalized risk stratification and holistic management for prevention of cognitive impairment in patients with different cardiovascular phenotypes

DORIAN GRAY

DORIAN GRAY project investigates the link between cardiovascular disease (CVD) and Mild Cognitive Impairment (MCI) in the ageing population. Its goal is to uncover underlying mechanisms to promote healthy, independent, and active living while reducing disease burden. Aligned with EU-Horizon Europe’s Strategic Plan on NCDs prevention, the project...

Funding Programme
Start Date
End Date
Total Funding
€ 10 921 114

Diagnostic and prognostic precision medicine for behavioral variant frontotemporal dementia

DIPPA-FTD

The behavioural variant of frontotemporal dementia (bvFTD) is a common cause of early-onset dementia that presents with changes in behavior and personality. It is often misdiagnosed and mistaken for a psychiatric disorder, such as depression or bipolar disorder. Unlike with Alzheimer’s disease, we still lack reliable tests that enable a diagnosis...

Funding Programme
Start Date
End Date
Total Funding
€ 1 320 000
European Countries Involved

Dipeptide-Repeat Vaccine to prevent ALS and FTD in C9orf72 mutation carriers

DPR-VAX

Neurodegenerative diseases are triggered by protein aggregation in the CNS, but developing therapies has been challenging. Since key disease mechanisms change during disease progression, halting further neuron loss has not been achieved and may not even improve the symptoms and survival. Causal therapy is most realistic for monogenic disease...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Do nanoparticles induce neurodegenerative diseases? Understanding the origin of reactive oxidative species and protein aggregation and mis-folding phenomena in the presence of nanoparticles

NEURONANO

As the use of nanoparticles becomes more prevalent, it is clear that human exposure will inevitably increase. Considering the rapidly ageing European population and the resulting increase in the incidence of neurodegenerative diseases, there is an urgent need to address the risk presented by nanoparticles towards neurodegenerative diseases. It is...

Funding Programme
Start Date
End Date
Total Funding
€ 4 823 050
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).